Tag: Radioligand therapy
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following ... Read More
Novartis to acquire US biopharma company Endocyte for $2.1bn
Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its ... Read More